Mounjaro - amhwellness.co.uk

Mounjaro

Average weight loss: Up to 22%*

Starting at

Medicines and Healthcare products Regulatory Agency

In November 2023, the MHRA authorized Mounjaro for weight management and weight loss, expanding its use beyond type 2 diabetes treatment.

Eli Lilly and Company

Eli Lilly invested £279M in 2024, partnering with the UK government to advance life sciences, including a five-year Manchester trial on Mounjaro’s weight loss effectiveness.

National Institute for Health and Care Excellence

NICE recommended Mounjaro for individuals with a body mass index (BMI) over 35 and at least one weight-related condition, facilitating its availability through the National Health Service (NHS).

Average of 20.2%% weight loss

*Mounjaro users saw 20.2% average weight loss over 72 weeks (Source)

How Semaglutide Works

Dual Hormone Activation

Mounjaro activates both GLP-1 and GIP receptors, enhancing insulin release when blood sugar is high while also reducing excess sugar production by the liver.

Slows Digestion

It delays stomach emptying, helping to regulate post-meal blood sugar spikes and promoting longer-lasting feelings of fullness.

Appetite Regulation

By influencing hunger signals in the brain, Mounjaro reduces cravings and helps control calorie intake, supporting effective weight management.

Average of 20.2%* weight loss

*Mounjaro users saw 20.2% average weight loss over 72 weeks (Source)

There's a reason why everyone is talking about AMH Wellness
It Works.

There's a reason why everyone is talking about AMH Wellness
It Works.

Select your Current Weight:

209 lbs

With us you could Lose:

42 lbs

Ready To Get Started On Your Weight Loss Journey?

Frequently asked question

Accordion Tab Title 1

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Accordion Tab Title 2

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Accordion Tab Title 3

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Accordion Tab Title 4

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Accordion Tab Title 5

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Accordion Tab Title 6

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.

Important Safety Information for Mounjaro (Tirzepatide) in the UK

Mounjaro (tirzepatide) is a prescription medication authorized in the UK for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related health conditions. It should be used alongside a reduced-calorie diet and increased physical activity.

Common Side Effects:

Nausea
Diarrhoea
Vomiting
Constipation
Indigestion
Stomach pain

These gastrointestinal side effects are common when initiating treatment and may decrease over time. If they persist or become bothersome, consult your healthcare provider.

Serious Side Effects:

While uncommon, serious side effects may occur:

Pancreatitis: Severe and persistent stomach pain that may radiate to your back.
Gallbladder Issues: Symptoms include pain in the upper stomach, fever, yellowing of the skin or eyes (jaundice).
Kidney Problems: Dehydration from nausea, vomiting, or diarrhoea can lead to kidney issues.
Allergic Reactions: Signs include swelling of the face, lips, tongue, or throat, and difficulty breathing.

If you experience any of these symptoms, seek medical attention immediately.

Warnings and Precautions:

Hypoglycaemia: When used with insulin or sulphonylureas, Mounjaro may increase the risk of low blood sugar. Monitor your blood sugar levels regularly.
diabetes.org.uk
Gastrointestinal Effects: Mounjaro has been associated with gastrointestinal adverse reactions, which may lead to dehydration and renal impairment. Patients should be advised to take precautions to avoid dehydration.
gov.uk
Thyroid Tumours: In animal studies, tirzepatide has been associated with thyroid C-cell tumours. It’s unclear if this applies to humans. Do not use Mounjaro if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Drug Interactions:

Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal supplements. Mounjaro may affect the absorption of oral medications due to delayed gastric emptying. Close monitoring is advised when taken with medications that have a narrow therapeutic window, such as warfarin.

Usage Instructions:

Administration: Inject Mounjaro once weekly, on the same day each week, at any time of day, with or without meals. It should be injected subcutaneously in the abdomen, thigh, or upper arm.
Dosage: Follow the dosing schedule as prescribed by your healthcare provider. Do not exceed the recommended dose.

Additional Considerations:

Hydration: Maintain adequate hydration, especially if experiencing gastrointestinal side effects.
Pregnancy and Breastfeeding: Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, as Mounjaro may not be recommended.
Storage: Store Mounjaro pens in the refrigerator. If needed, they can be kept at room temperature (up to 30°C) for up to 21 days.

Reporting Side Effects:

If you experience any side effects, report them to your healthcare provider or directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Always consult with your healthcare provider for personalized medical advice before starting or stopping any medication.

Ref: medicines.org.uk